NO960393D0 - Heterocyclic phenyl compounds as COX-2 inhibitors - Google Patents

Heterocyclic phenyl compounds as COX-2 inhibitors

Info

Publication number
NO960393D0
NO960393D0 NO960393A NO960393A NO960393D0 NO 960393 D0 NO960393 D0 NO 960393D0 NO 960393 A NO960393 A NO 960393A NO 960393 A NO960393 A NO 960393A NO 960393 D0 NO960393 D0 NO 960393D0
Authority
NO
Norway
Prior art keywords
cox
inhibitors
phenyl compounds
heterocyclic phenyl
heterocyclic
Prior art date
Application number
NO960393A
Other languages
Norwegian (no)
Other versions
NO960393L (en
Inventor
Yves Ducharme
Jacques Yves Gauthier
Petpiboon Prasit
Yves Leblanc
Zhaoyin Wang
Serge Leger
Michel Therien
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/179,467 external-priority patent/US5474995A/en
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO960393D0 publication Critical patent/NO960393D0/en
Publication of NO960393L publication Critical patent/NO960393L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
NO960393A 1994-01-10 1996-01-30 Heterocyclic phenyl compounds as COX-2 inhibitors NO960393L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors
PCT/CA1994/000688 WO1995018799A1 (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors

Publications (2)

Publication Number Publication Date
NO960393D0 true NO960393D0 (en) 1996-01-30
NO960393L NO960393L (en) 1996-07-09

Family

ID=22656713

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960393A NO960393L (en) 1994-01-10 1996-01-30 Heterocyclic phenyl compounds as COX-2 inhibitors

Country Status (12)

Country Link
EP (1) EP0739340A1 (en)
JP (1) JP2788677B2 (en)
CN (1) CN1143365A (en)
AU (1) AU1269495A (en)
BG (1) BG63082B1 (en)
BR (1) BR9408478A (en)
CA (1) CA2180651A1 (en)
FI (1) FI108792B (en)
HU (1) HUT74986A (en)
NO (1) NO960393L (en)
SG (1) SG43841A1 (en)
WO (1) WO1995018799A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
HU225506B1 (en) * 1995-07-19 2007-01-29 Merck & Co Inc Use of 4-(4-methylsulfonyl-phenyl)-3-phenyl-2-(5h)-furanone for the preparation of medicaments treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
SK284330B6 (en) * 1996-05-17 2005-01-03 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
CA2283399C (en) * 1997-03-14 2006-02-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US6136831A (en) * 1997-04-11 2000-10-24 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and COX inhibitors containing them
AU7237998A (en) * 1997-05-16 1998-12-08 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
ES2203985T3 (en) 1997-09-05 2004-04-16 Glaxo Group Limited DERIVATIVES OF 2,3-DIARIL-PIRAZOLO (1,5) PIRIDAZINE, ITS PREPARATION AND ITS USE AS INHIBITORS OF CYCLLOXYGENASE 2 (COX-2) `.
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
SA99191255B1 (en) 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
ES2328446T5 (en) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Use of lysosomal acid lipase to treat atherosclerosis and associated diseases
US6465509B2 (en) 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
DE10133665A1 (en) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carboxylic acid derivatives, medicaments containing these compounds, their use and preparation
PT3072978T (en) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
CA2489428A1 (en) 2002-06-27 2004-01-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
KR20050051729A (en) * 2003-11-28 2005-06-02 일양약품주식회사 Process for preparing phenyl heterocycles as a cyclooxygenase-2 inhibitor
DE102004027912A1 (en) 2004-06-09 2005-12-29 Grünenthal GmbH Substituted cyclopentene compounds
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
KR101310037B1 (en) 2005-05-31 2013-09-24 밀란 인크. Compositions comprising nebivolol
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP3279663B1 (en) 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
BRPI0810409A2 (en) 2007-04-18 2015-02-18 Thethys Bioscience Inc DIABETES-RELATED BIOMARKERS AND METHODS OF USE
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
CN104640856B (en) 2012-05-11 2017-09-15 复位治疗公司 Carbazole-containing sulfonamides as cryptochrome modulators
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
TWI690521B (en) 2014-04-07 2020-04-11 美商同步製藥公司 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388909A3 (en) * 1989-03-22 1991-05-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
WO1991016055A1 (en) 1990-04-17 1991-10-31 Allergan, Inc. 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
EP0679157B1 (en) * 1993-01-15 1997-11-19 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
NZ271833A (en) * 1993-08-19 1997-08-22 Warner Lambert Co Substituted 2(5h)-furanone (or thiophenone or pyrrolone) derivatives

Also Published As

Publication number Publication date
FI962800A0 (en) 1996-07-09
CA2180651A1 (en) 1995-07-13
EP0739340A1 (en) 1996-10-30
AU1269495A (en) 1995-08-01
FI108792B (en) 2002-03-28
HUT74986A (en) 1997-03-28
HU9601875D0 (en) 1996-09-30
BG100350A (en) 1996-12-31
NO960393L (en) 1996-07-09
JPH09506631A (en) 1997-06-30
WO1995018799A1 (en) 1995-07-13
BR9408478A (en) 1997-08-26
SG43841A1 (en) 1997-11-14
BG63082B1 (en) 2001-03-30
FI962800L (en) 1996-09-06
JP2788677B2 (en) 1998-08-20
CN1143365A (en) 1997-02-19

Similar Documents

Publication Publication Date Title
FI962800A0 (en) Phenyl heterocyclic compounds as COX-2 inhibitors
DK1001934T3 (en) Indole compounds as COX-2 inhibitors
FI965126A7 (en) Tri-substituted phenyl derivatives useful as PDE IV inhibitors
PT996622E (en) NEW ESPEROAZABICICLIC HETEROCYCLIC COMPOUNDS
DK2253620T3 (en) SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN-TYROSINKINASE INHIBITORS
DK0925287T3 (en) Heterocyclic metalloprotease inhibitors
ATE226573T1 (en) HETEROCYCLIC METALLOPROTEASE INHIBITORS
FI962749L (en) New heterocyclic compounds
IS5843A (en) Phenyl yanthine derivatives
DK1100797T3 (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes
EE9900259A (en) New form of compound
DE69906311D1 (en) DIARYLBENZOPYRANE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS
NO992725L (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
DK1027332T3 (en) New lactametalloprotease inhibitors
PT907650E (en) N-¬4- (HETEROYARMETHYL) PHENYL HETEROARYLAMINESC
DK1060178T3 (en) Heterocyclic compounds as inhibitors of rotamase enzymes
FI990922L (en) New compounds
DK0820451T3 (en) New Heterocyclic Compounds
ATE252547T1 (en) MATRIXMETALLOPROTEINASE INHIBITORS
DK0944601T3 (en) Heterocyclic quanidinylamino compounds as alpha-2-adrenoceptor agonists
NO993161L (en) cyclooxygenase inhibitors
NO995430D0 (en) New heterocyclic compounds
FI963509A0 (en) Isoxazoline Compounds as 5-Lipoxygenase Inhibitors
FI941265A7 (en) Heterocyclic sulfonamidothrombin inhibitors
ID18481A (en) 2- (3,5-DIFLUOROFENIL) -3- (4-METYLSULFONIL) FENIL) -2-CYCLOPENTEN-1-ON USING AS COX-2 INHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application